Jaeger, Hannah K.
Davis, David A.
Nair, Ashwin
Shrestha, Prabha
Stream, Alexandra
Yaparla, Amulya
Yarchoan, Robert
Funding for this research was provided by:
National Institutes of Health
Article History
Received: 5 April 2023
Accepted: 4 July 2023
First Online: 18 July 2023
Competing interests
: Drs. Yarchoan and Davis are co-inventors on US Patent 10,001,483 entitled “Methods for the treatment of Kaposi’s sarcoma or KSHV induced lymphoma using immunomodulatory compounds, and uses of biomarkers”. In is our understanding that foreign patents have also been filed for this invention. An immediate family member of R. Yarchoan is a co-inventor on patents or patent applications related to internalization of target receptors, epigenetic analysis, and ephrin tyrosine kinase inhibitors. These inventions were all made as full-time employees of the US government under 45 Code of Federal Regulations Part 7. All rights, title, and interest to these patents have been or should by law be assigned to the U.S. Department of Health and Human Services. The government conveys a portion of the royalties it receives to its employee inventors under the Federal Technology Transfer Act of 1986 (P.L. 99–502). This research was supported in part by a CRADA between the NCI and Celgene Corporation (now Bristol Myers Squibb). Dr. Yarchoan also reports receiving drugs for clinical trials from Merck, EMD-Serano, Eli Lilly, and CTI BioPharma through CRADAs with the NCI, and he has received drug supply for laboratory research from Janssen Pharmaceuticals.